Dr. Garutti on the Potential Shift to Neoadjuvant Therapy in Melanoma

Mattia Garutti, MD, medical oncologist, Unit of Clinical Oncology, Centro di Riferimento Oncologico di Aviano, Aviano, Italy, discusses the potential shift to neoadjuvant therapy in melanoma.

Patients with stage III melanoma have a high risk of relapse, says Garutti. As such, developing new therapies to increase the rates of cure among patients is a critical area of research.

Moreover, the potential shift from adjuvant therapy to neoadjuvant therapy may usher in a new era of melanoma management, Garutti explains.

In other cancer types, such as breast cancer, neoadjuvant therapy has become the gold standard of treatment, Garutti says.

As such, similar utilization of neoadjuvant therapy may be introduced to the melanoma space in the near future, Garutti concludes.